To order this 600+page report, which features 190+ figures and 280+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Key Market Insights
§ Eminentrepresentatives from different biopharmaceutical companies confirm thesustained interest in ADC therapeutics, highlighting the technologicalinnovation that is driving contemporary R&D initiatives
§ Presently, over 240 ADC therapy candidates are being evaluated inclinical / preclinical stages for treating a variety of solid tumors /hematologic cancers
§ The pipeline featuresproduct candidates that target a wide range of biological antigens and areequipped with different cytotoxic warheads; a number of companies are focused on developing novel drug conjugates
§ In order to gain acompetitive edge in the market, ADC developers are actively exploring newbiological targets, conducting clinical trials across different geographies totreat diverse disease indications
§ A number of eminent scientists from renowned universities, owing totheir involvement in clinical development efforts, have emerged as key opinionleaders within this market
§ Over the years, more than 16,000 patents related to ADCs have been filed/ granted across the world, indicative of the ongoing pace of R&D activityin this field of research
§ Several investors, having realized the opportunity within this upcomingsegment of targeted cancer therapeutics industry, have invested over USD 5billion, in the period between 2011 and 2019
§ The increasing interest in this field is also reflected in thepartnership activity; deals inked in the recent past were mostly focused onlicensing of products / technologies, involving both international andindigenous stakeholders
§ In the recent years,several developer companies have initiated clinical trials to evaluate thetherapeutic potential of ADCs in combination with other drug / therapy classes
§ Anticipating the launch of several product candidates, stakeholders areexploring diverse commercialization strategies across different stages of thelaunch cycle along with the appropriate reimbursement strategies
§ Given thecomplexities associated with the development and production of ADCs, CMOs areindispensable to the R&D and manufacturing activity in this domain; someCMOs have even pioneered the novel ADC technology platforms
§ Case Study: In order to keep patients andhealthcare professionals informed and aware of the developments, companies aredeploying diverse promotional strategies for their respective products
§ With a promising development pipeline and encouraging clinical results,the global market is anticipated to witness growth at an annualized rate ofover 20% during the next decade
§ The anticipatedfuture opportunity is likely to be distributed across different types of linkers and target antigens as more late-stage drugs get commercialized andexisting marketing authorizations are expanded
For more information,please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
